The Boston NETT Group is a local consortium of hospitals dedicated to offering patients the most cutting edge clinical trials in neurologic emergencies.
Welcome to the Boston NETT Group
The Boston Neurological Emergencies Treatment Trials (Boston NETT) Group is a team of local hospitals participating in a national, federally-funded research effort to develop new treatments for patients with acute diseases and injuries to the brain, spinal cord, and peripheral nervous system. Current and future NETT research studies aim to improve care for patients with stroke, traumatic brain injury, and spinal cord injury. Rapid diagnosis and early treatment are critical for improving outcomes in patients with neurologic emergencies, and the NETT will therefore conduct these studies on the front lines of emergency medicine, in cooperation with colleagues in neurology, neurosurgery, critical care, pre-hospital care, and trauma.
This is an exciting opportunity to improve patient care in the emergency setting. We appreciate your interest, participation, and feedback. Welcome to the Boston NETT Group!
Joshua Goldstein, MD, PhD
The Boston NETT Group
Current NETT studies
These clinical trials are currently enrolling patients at NETT sites nation-wide.
SHINE – Stroke Hyperglycemia Insulin Network Effort
SHINE aims to determine the most effective and safest way to control blood sugar levels in patients with an acute stroke and high blood sugar. Patients who enroll in SHINE will receive either insulin intravenous (IV) infusion (in the study treatment group) or saline (salt water) infusion with insulin injections (in the study control group) within 12 hours of the start of their stroke symptoms. Patients who enroll in the study will have their neurological outcomes measured 90 days after their stroke, using an exam called the modified Rankin Scale (mRS) score. To determine the effectiveness of the treatments, study doctors will compare the 90-day mRS scores of the study treatment and control groups. To determine the safety of the treatments, the study doctors will look at the rates of low blood sugar and worsening neurological outcomes that occur in both the study treatment and control groups.
ProTECT III – Progesterone for the Treatment of Traumatic Brain Injury
Traumatic brain injury (TBI) is a major cause of premature death and disability worldwide. With the exception of mannitol, no therapy has been found to be effective in reducing mortality and improving functional outcomes for patients with TBI. Progesterone is a steroid found to have powerful neuroprotective properties in multiple different animal models of brain injury. Based on encouraging pilot clinical trial results, the ProTECT trial will determine the efficacy and confirm safety of progesterone treatment for adults with moderate to severe TBI.
POINT – Platelet Oriented Inhibition in New TIA
Transient ischemic attacks (TIA) are common, with an estimated 250,000-350,000 occurring each year in the US. Patients with TIA often have rapid recovery of blood flow to the brain, which makes TIA different from completed stroke, where recovery is much longer. Many studies have shown that the short-term risk of stroke is high after TIA, particularly in the first few days, even in patients treated with aspirin, which is the current standard of care. Additional effective therapies in those with TIA could significantly reduce the overall burden of stroke if they are started right away. However, no large-scale research study has tested the safety or effectiveness of an acute treatment in patients with TIA. The POINT study aims to determine whether clopidogrel (Plavix) is effective in reducing the 90-day risk of stroke, myocardial infarction (heart attack), and ischemic vascular death when begun within 12 hours of TIA onset in patients taking aspirin.